Shares of AngioDynamics Inc. (NASDAQ:ANGO) dropped 1.2% on Tuesday . The company traded as low as $16.51 and last traded at $16.56, with a volume of 67,421 shares. The stock had previously closed at $16.76.

Separately, Zacks Investment Research upgraded shares of AngioDynamics from a “sell” rating to a “hold” rating in a research note on Monday, May 2nd. Five research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. AngioDynamics has an average rating of “Hold” and a consensus target price of $14.10.

The company’s 50 day moving average is $15.88 and its 200-day moving average is $12.99. The stock’s market cap is $599.87 million.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Wednesday, July 13th. The company reported $0.19 EPS for the quarter, topping the consensus estimate of $0.16 by $0.03. The firm had revenue of $93.40 million for the quarter, compared to analyst estimates of $88.64 million. The company’s revenue was up 2.8% on a year-over-year basis. During the same quarter last year, the firm earned $0.14 EPS. Equities research analysts expect that AngioDynamics Inc. will post $0.63 EPS for the current year.

In other AngioDynamics news, Director David F. Burgstahler sold 2,250,000 shares of the business’s stock in a transaction that occurred on Friday, August 5th. The shares were sold at an average price of $14.62, for a total transaction of $32,895,000.00. Following the completion of the transaction, the director now owns 23,988 shares in the company, valued at approximately $350,704.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Avista Capital Partners Gp, Ll sold 2,241,000 shares of the business’s stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $14.62, for a total transaction of $32,763,420.00. The disclosure for this sale can be found here.

AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease, and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.